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Abstract
Humanized mouse models offer a challenging possibility to study human cell function in vivo. In the huPBL-SCID-huSkin
allograft model human skin is transplanted onto immunodeficient mice and allowed to heal. Thereafter allogeneic human
peripheral blood mononuclear cells are infused intra peritoneally to induce T cell mediated inflammation and microvessel
destruction of the human skin. This model has great potential for in vivo study of human immune cells in (skin)
inflammatory processes and for preclinical screening of systemically administered immunomodulating agents. Here we
studied the inflammatory skin response of human keratinocytes and human T cells and the concomitant systemic human T
cell response. As new findings in the inflamed human skin of the huPBL-SCID-huSkin model we here identified: 1.
Parameters of dermal pathology that enable precise quantification of the local skin inflammatory response exemplified by
acanthosis, increased expression of human b-defensin-2, Elafin, K16, Ki67 and reduced expression of K10 by microscopy and
immunohistochemistry. 2. Induction of human cytokines and chemokines using quantitative real-time PCR. 3. Influx of
inflammation associated IL-17A-producing human CD4+ and CD8+ T cells as well as immunoregulatory CD4+Foxp3+ cells
using immunohistochemistry and -fluorescence, suggesting that active immune regulation is taking place locally in the
inflamed skin. 4. Systemic responses that revealed activated and proliferating human CD4+ and CD8+ T cells that acquired
homing marker expression of CD62L and CLA. Finally, we demonstrated the value of the newly identified parameters by
showing significant changes upon systemic treatment with the T cell inhibitory agents cyclosporine-A and rapamycin. In
summary, here we equipped the huPBL-SCID-huSkin humanized mouse model with relevant tools not only to quantify the
inflammatory dermal response, but also to monitor the peripheral immune status. This combined approach will gain our
understanding of the dermal immunopathology in humans and benefit the development of novel therapeutics for
controlling inflammatory skin diseases.
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Introduction
The in vivo study of human biological processes is severely
limited by ethical and technical constraints. An attractive relevant
alternative is the use of humanized mice or ‘‘mouse-human
chimaeras’’. Humanized mice are immunodeficient mice that are
engrafted with human tissue or cells, such as hematopoietic stem
cells (HSCs) or peripheral blood mononuclear cells (PBMC).
Humanized mice offer a valuable tool in pre-clinical drug testing
in translational medicine and investigations of human biology in
areas like cancer, (auto-) inflammation/immunity, infectious
diseases and immunotherapy [1,2].
Several humanized mouse models have been described to study
T cell mediated skin diseases [3–7]. In these models, healthy
human skin, diseased-prone skin or bioengineered skin is
transplanted onto immunodeficient mice, allowed to become
vascularized and heal, and in some of these models human
immune cells are infused that will reconstitute the recipient with
human immune cells to induce skin inflammation [5,6]. Although
all these models have advantages and disadvantages their
application to drug discovery and for the development of cellular
therapies has already proven to be fruitful [8–11].
To study the local inflammatory as well as the systemic human
T cell response in vivo we focused on the human peripheral blood
lymphocyte reconstituted severe combined immunodeficient
PLOS ONE | www.plosone.org 1 October 2012 | Volume 7 | Issue 10 | e45509
mouse (SCID) human skin allograft model ( huPBL-SCID-
huSkin model ) initially described by Pober’s group [5,6]. In this
model human skin is transplanted on to immunodeficient SCID/
beige mice, and since these recipients lack functional mature T
and B cells and have impaired NK cell- and macrophage
function [12,13], human skin is revascularized and accepted.
After healing of the human skin, allogeneic human PBMC are
infused intra peritoneally (ip), resulting within 2–3 weeks in
microvascular cell injury and human T cell infiltration of the
human skin [5,6]. This model is of particular interest to study the
local pathology of skin inflammation. For this purpose it is
crucial to be able to quantify the cutaneous inflammatory
response by clinical relevant parameters associated with dermal
inflammation, such as inflammation-associated deregulated
expression of keratinocyte differentiation markers and charac-
terization and enumeration of skin infiltrating human lympho-
cytes. This information has not previously been published
regarding this model.
Most studies on inflammation in humanized mouse models
focus on the local site of inflammation. A caveat in these
humanized mouse models is the study of the systemic immuno-
logical response, which besides the local site of inflammation is
crucial in the generation and regulation of the immune program
(e.g, effector Thelper Th1, Th2, Th17, or regulating suppressor
Treg). Important steps in mounting a T cell immune response
include T cell activation, differentiation and expansion in the
draining lymph nodes. Activated T cells leave the lymph node via
the efferent lymphatics and enter the circulation through the
lymph-vascular system and depending on their homing imprint
the cells migrate into tissues or colonize other immune
compartments [14,15]. Moreover, inflammatory skin diseases,
such as moderate to severe psoriasis, are traditionally treated with
systemic medication such as methotrexate, retinoids, and
cyclosporine A and more recently with biologicals such as anti-
TNF or anti-p40 therapy. This systemic treatment will not only
influence the local skin immune response, but will also interfere
systemically with T cell activation, differentiation, expansion and
homing. At present, little Information is available on the effects of
systemic medication of immune modulating agents and their
effects on the systemic immune response in humanized mouse
models. This information is crucial to identify treatment-related
systemic biomarkers for immunomonitoring of patients undergo-
ing clinical trials.
In the present study, both local human skin inflammatory
processes as well as systemic human CD4+ and CD8+ T cell
responses in the huPBL-SCID-huSkin model were studied. As
new findings in this model we identified relevant markers of
human dermal pathology such as aberrant expression of hBD2,
Elafin, K10 and K16, enabling quantification of the local skin
inflammatory response by keratinocytes, markers for T cell
mediated responses in the skin, as well as, chemokine and
cytokine induction and analysis of IL-17A-producing and
Foxp3+ T cells. Also, we determined markers that enable
quantitative analysis of systemic immune activation responses.
Human skin inflammation was paralleled by the presence of
CD4+Foxp3+ T cells, suggesting that immune regulatory
pathways are serving to limit human tissue inflammation.
Unraveling these pathways of human cells in this in vivo model
will undoubtedly offer novel therapeutic strategies for controlling
autoimmune tissue responses.
Results
Acanthosis and aberrant epidermal marker expression of
hBD2, Elafin, K10 and K16 in the inflamed human skin in
the huPBL-SCID-huSkin allograft model
Here we set out to define and quantify clinical relevant dermal
parameters in the inflamed human skin the huPBL-SCID-huSkin
allograft model as initially described by Pober’s group [5,6]. The
model in brief, after grafting and healing of human skin onto
immunodeficient SCID beige recipients, allogeneic human PBMC
are infused intra peritoneally (i.p.), which results in microvessel
destruction and human T cell influx of the human skin graft [5,6].
Using histological microscopic examination of the human skin
(Fig. 1A) we demonstrated hyperkeratosis (thickened keratinized
upper layer), parakeratosis (nucleated keratinocytes in the corni-
fied layer), acantosis (abnormal epidermal thickening, 155,1610,6
vs 315,9639,4 mm; PBS vs huPBMC, resp, p,0,01)(Fig. 1B),
exocytosis (lymphocytes in the epidermis), spongiosys (intercellular
edema between the keratinocytes and elongated rete ridges
(fingerlike epidermal projections into the dermis) such as often
observed in psoriatic lesions (Fig. 1A).
Using immunohistochemistry we quantitatively demonstrated
that the changes in skin morphology were paralleled by a
significant induction of keratinocyte associated inflammatory
markers such as human b-defensin-2 (hBD2; 12,562,1 vs
31,7610,9, p,0,01), Elafin (22,462,5 vs 43,0614,7, p,0,05)
and the hyper-proliferative marker keratin-16 (K16; 11,361,0 vs
38,6612,5, p,0,01) , and down regulation of normal supra-basal
keratin-10 (K10; 59,361,6 vs 11,664,9, p,0,01) (Fig. 1C).
Up-regulation of Ki67 expression by the keratinocytes indicated
the presence of an increased number of dividing cells in the
epidermis, which supports ongoing epidermal hyper-proliferation
(Fig. 1D). Normal supra-basal K10 expression was found in the
human skin transplants in the absence of PBMC infusion,
indicating that the transplant procedure did not disturb normal
supra-basal K10 expression (Fig. 1C).
In summary, as a new finding we defined deregulated epidermal
marker expression of hBD2, Elafin, K10, K16 and Ki67 in the
inflamed human skin of the huPBL-SCID-huSkin model that can
be employed to analyze the local inflammatory skin response in
quantitative way.
Human T cell infiltration and detection of human
chemokines and cytokines in the inflamed human skin
Next to the epidermal changes described above, we found
mononuclear cell infiltrates, including human CD3+ T cells, with
a diffuse distribution throughout the human skin, but not in the
mouse skin (Fig. 2A+B). Control mice that were transplanted with
human skin and which received PBS instead of huPBMC showed
no evidence of inflammation in either epidermis or dermis
(Fig. 1A).
Inflammation of lymphocytes is regulated by pro-inflammatory
cytokines and chemokines that attract these immune cells. To
assess if human cytokines and chemokines might be involved in the
development of skin inflammation in the huPBL-SCID/skin
allograft model we determined gene expression levels in the skin
grafts using quantitative real time PCR (qPCR). To this end the
human skin grafts were removed 21 days after infusion of PBMC,
at this time point clear inflammation hallmarks were observed by
histology and immunohistochemistry (Fig. 1,2A). From the centre
of the human skin grafts 4 mm punch biopsies were taken and
subsequently prepared for qPCR analysis. A clear increase in gene
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expression of the proinflammatory human cytokines IL1B, IL6
and IL8 was observed in the PBMC-injected skin compared to the
PBS-treated controls (Fig. 2B). Also, we found increased gene
expression of the human chemokines CXCL1, CXCL10 and
CCL5, as well as DEFB4, the gene encoding the antimicrobial
peptide human beta defensin-2 (hBD2) which was recently
demonstrated to attract CCR6 expressing cells [16]. mRNA levels
of human cytokines exclusively or predominantly expressed by
immune cells were close to or below the detection limit in either
some of the PBS-injected controls (e.g. IFNc which is clearly
induced in the treated skin) or in both treated and control skin
samples (such as IL12B, IL23A, IL17A, IL22 and IL20)
Infiltration of CD4+ and CD8+ IL-17A-producing T cells
and CD4+ Foxp3-expressing T cells in the inflamed
human skin
Next, we further characterized the mononuclear cell infiltrate in
the skin by immunohistochemistry, and focused our analysis on
quantification of human CD4+ and CD8+ T cells. As reported
previously on the huPBL-SCID/skin allograft model [5,6] the
human skin contained both CD4+ and CD8+ T cells (Fig. 3A).
CD4+ T cell infiltrates were predominantly present within the
dermis (296,56686,52 vs 954,68635,9 cells/mm2, PBS vs
huPBMC, respectively, p,0,01), while CD8+ T cells were present
in both dermis (245,42610,3 vs 1162,856107,8 cells/mm2
p,0,05) and epidermis (296,6686,5 vs 954,76309,4 cells/mm2
p,0,05) (Fig. 3B).
The cytokine interleukin 17A, which amongst other cell types is
produced by T cells, has strong pro-inflammatory potential and
has been clearly associated with psoriasis [17–19], and it also
contributes to the pathology of atopic dermatitis [20,21].
Therefore, we analyzed the in vivo potential of the human CD4+
and CD8+ T cells to produce IL-17A in this huPBL/SCID model.
IL-17A-producing cells were clearly present in the dermis, at the
basal layer and also in the epidermis (Fig. 3C); both human
CD4+/IL-17A+ and CD8+/IL-17A+ (41.95612.38 and
27.865.97 cells/mm2, resp.) were observed (Fig. 3D). Next to
these IL-17 –producing T cells, also CD3 negative IL-17-
producing cells were observed. Mast cells and neutrophils are
known for their IL-17A producing potential [22]. Here, we could
clearly demonstrate that in the inflamed human skin human IL-17
production was associated with tryptase+ human mast cells, while
we could not demonstrate IL-17+ elastase+ human neutrophils
(Fig. 3E). We could not demonstrate IL-17A in the serum of the
mice 3 weeks after infusion of huPBMC (data not shown), which
suggests that IL-17 plays a predominant role in the local
inflammatory skin response.
As opposed to pro-inflammatory cells, anti-inflammatory cells
are needed to regulate the immune response. CD4+ regulatory T
cells that express the transcription factor Foxp3 are renowned for
their immunosuppressive potential and control of proinflamma-
tory T cells. Therefore we analyzed the presence of human
Foxp3+ cells in the human skin of the huPBL-SCID-huSkin
model. CD4+ Foxp3+ cells were mainly present at the basal layer
(Fig. 3F).
Taken together, inflammation of the human skin transplant of
the huPBL-SCID-huSkin model is characterized by aberrant
epidermal differentiation, presence of human cytokines and
chemokines and influx of CD4+ and CD8+ T cells and mast cells
that are able to produce the proinflammatory cytokine IL-17 as
well as the presence of putative anti-inflammatory Foxp3
expressing CD4+ T cells.
Local human skin inflammation in the huPBL-SCID-
huSkin model is paralleled by systemic CD4 and CD8 T
cell activation, proliferation and acquisition of homing
markers
In addition to the analysis of the local inflammatory response in
the human skin, we studied the systemic response of the CD4+ and
CD8+ T cells in the huPBL-SCID-huSkin model. Mice were
transplanted with human skin that was allowed to heal for 3 weeks
and subsequently inoculated with 1506106 human PBMC (i.p.) as
describe above. After 3 weeks the CD4+ and CD8+ T cells were
enumerated in peripheral blood, spleen and lymph nodes, and
these cells were analyzed for cell division status, activation and
homing marker expression using flowcytometry.
Anti-human CD45 monoclonal antibody was used to detect
human lymphocytes in the humanized mice. CD45-expressing
CD4+ and CD8+ T cells were observed in the peripheral blood,
spleen and lymph nodes of the huPBL-SCID-huSkin model
(Fig. 4A). In the peripheral blood equal percentages of CD4+
(42,365,5%) and CD8+ (48,567,6%) T cells were found (Fig. 4A),
whereas in the lymph nodes CD4+ T cells (58,963,7%) were more
predominant as compared to CD8+ T cells (27,763,9%)(Fig. 4B).
Although less clear, the spleen seemed to contain more CD8+
(55,066,9%) than CD4+ T cells (30,262,0%) (Fig. 4B).
The majority of human T cells present in spleen, lymph nodes
and peripheral blood expressed the memory marker CD45RO
(Fig. 4C,D). Given that the inoculated huPBMC population pre-
infusion contained about 60% CD45RA expressing T cells
(Fig. 4D), which is indicative for the presence of naı¨ve T cells,
this suggests that the naı¨ve T cells became activated in vivo. The
presence of an allogeneic human skin transplant was required to
induce this activated phenotype in vivo, as in the absence of a
human skin transplant higher number of naı¨ve CD45RA+ were
observed spleen and lymph nodes (Fig. 4C). Irrespective of
whether human skin was grafted, in peripheral blood we found
similar percentages (.90%) of CD45RO+ cells (Fig. 4C). It
should however be emphasized that higher absolute CD45RO+
numbers were found when a skin transplant was present (approx.
Figure 1. Acanthosis and aberrant epidermal marker expression of hBD2, Elafin, K10 and K16 in the inflamed human skin of the
huPBL-SCID-hu Skin allograft model. A. Histology (H&E staining) of human skin grafts from SCID beige mice 21 days after infusion (i.p.) of
huPBMC. Representative photographs are shown after PBS (left photograph) and huPBMC infusion (right photograph). Photograph shows increased
epidermal thickness (acanthosis) and elongated fingerlike epidermal projections into the dermis (rete ridges) and large lymphocyte infiltration after
huPBMC infusion. Abnormal presence of nuclei in the stratum corneum (parakeratosis) and infiltration of lymphocytes in the epidermis (exocytosis)
(bottom-right photograph). 206, 206, 406magnifications respectively. B. Quantitative microscopic histological analysis of the epidermal thickness
(mm) of human skin grafts following infusion of PBS and huPBMC. Mean6SEM are shown for n = 3 and 6 upon PBS and huPBMC infusion resp. C.
Immunohistochemistry of K10, K16, hBD2 and Elafin (brown) in human skin grafts from SCID beige mice 21 days after infusion (i.p.) of PBS (top panels)
or huPBMC (lower panels). Photograpsh show representative examples, summarized data are given in the figures. Mean6SEM percentages of the
area positive for the indicated markers is shown for n = 3 and 5–8 upon PBS and huPBMC infusion resp. 106magnification. D. Ki-67 expression
(brown) in the stratum basale of the epidermis. The insert shows a higher magnification. A representative example of n = 12 is shown. 206
magnification. Graphs show summarized data of Ki67+ cells/mm length of basement membrane after PBS or huPBMC infusion in human skin biopsies
(mean6SEM, of n = 4 and 6, resp.).
doi:10.1371/journal.pone.0045509.g001
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Figure 2. Induction of human chemokines and cytokines and influx of human T cells in the dermis and in the epidermis of huPBL-
SCID-hu Skin allograft model. A. Images show representative panoramic overviews (H&E staining) of human skin grafts from SCID beige mice 21
days after infusion (i.p.) of PBS (top) or huPBMC (below). Note that human epidermis is thicker than the mouse epidermis (present in the left edge of
the specimen in the top image and in both edges in the bottom image) and in contrast with human skin, mouse skin has closely spaced hair folicules
troughout the epidermis. Images were composed using PTGui software (New House Internet Services B.V.; http://www.ptgui.com/). B.
Immunohistochemistry of human CD3+ (brown) T cell infiltration in the human dermis and epidermis, 21 days after infusion of huPBMC.
Representative example of n = 12 are shown. 206magnification. C. Gene expression analysis using quantitative real-timePCR of human cytokine and
chemokine transcripts in the human skin 21 days after infusion of huPBMC. Figure shows fold increase in cytokine and chemokine mRNA expression
levels after huPBMC infusion as compared to PBS infusion (n = 5 and 3; huPBMC and PBS resp.).
doi:10.1371/journal.pone.0045509.g002
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56104 vs. 16102 CD45RO+ cells in 20 ml retro-orbital blood samples
after human skin transplantation vs. no transplantation, resp.) In
peripheral blood, and spleen we found proliferating human CD4+
and CD8+ cells, as indicated by Ki67 staining (Fig. 4E,F).
Interestingly, we observed that the presence of a human skin graft
led to the induction of cutaneous lymphocyte associated antigen
(CLA) expression on peripheral CD3+ T cells (Fig. 4G,H). This
was not the case for the lymph node homing marker CD62L
(Fig. 4G,H). It appeared that in particular CD8+ T cells had
acquired CLA expression which was observed in both peripheral
blood cells and spleen, but not in the case of lymph nodes
(Fig. 4I,J). This indicates that the human skin can instruct homing
receptor expression of the inoculated human cells in this
humanized mouse model. Moreover, we found that more CD4+
T cells as compared to CD8+ T cells in the peripheral blood
expressed the lymph node homing marker CD62L (Fig. 4I,J).
In summary, the flowcytometric analysis of human CD4+ and
CD8+ T cells in peripheral blood and lymphoid organs in the
huPBL-SCID-huSkin humanized mouse enables the study of the
immune status and homing of human T cells in vivo. This together
with the study of the local inflammatory response, as described
above, empowers the huPBL-SCID-huSkin model as an important
tool in the development and preclinical evaluation of novel
systemic immunomodulating agents.
Cyclosporin-A and rapamycin prevent human T cell
mediated skin inflammation and systemic activation and
proliferation of the human T cells
Next, we studied the value of the above mentioned newly
identified parameters in the huPBL-SCID-huSkin allograft model
by analyzing the effect of systemic treatment with the T cell
inhibitory agents cyclosporine-A and rapamycin. We used the
combination of Cyclosporine (CsA) and Rapamycin (Rapa), which
has previously been demonstrated to decrease the extent of
mononuclear cell infiltration and reduce the degree of microvessel
injury in a huPBL-SCID-huSkin model [6]. Administration of CsA
(0,4 mg/kg/day) was started at the day of inoculation with the
huPBMC. Co-administration of Rapa (0,4 mg/kg/day) was
initiated at day 7 and given on alternate days until the end of
the immunosuppressive treatment.
Macroscopic evaluation 21 days after inoculation with
huPBMC indicated that treatment with CsA and Rapa reduce
visible signs of inflammation; the skin graft looked healthier and
less inflamed, as indicated by a reduction in erythema, scaling and
skin thickness (Fig. 5A). Histological analysis revealed that the
epidermal thickening, elongated rete ridge formation and mono-
nuclear cell infiltrates induced in this humanized mouse model was
effectively inhibited by combined CsA and Rapa treatment
(Fig. 5B). Quantitative microscopic analysis clearly demonstrated
a significant reduction in epidermal thickening by CsA and Rap
treatment (315,9668,2 vs 135,4645,1 mm, no treatment vs
CsA+Rapa, resp, p,0,05)(Fig. 5B). Immunohistochemistry
revealed that the aberrant epidermal differentiation, as indicated
by the increased hBD2 and Elafin expression, and dysregulated
K10/K16 expression, in the human skin were significantly
inhibited following CsA and Rapa treatment (hBD2; 40,262,9
vs 12,265,2, Elafin; 2462 vs 14,464,K10; 18,963,4 vs 43,666,8,
K16; 73,364,7 vs 17,8610% positive area, no treatment vs
CsA+Rapa, resp, p,0,05) (Fig. 5C,D). As expected, the number
of CD4+ and CD8+ T cells in the human dermis (CD4;
783,5638,8 vs 251,1642,9, CD8; 1162,96716,3 vs 71,3638,4
cells/mm2, no treatment vs CsA+Rapa, resp, p,0,05 and p,0,01)
and epidermis (CD4; 605,8676,6 vs 296,6635,6, CD8;
1232,56648,4 vs 183,9,9610,7 cells/mm2, both p,0,01) were
significantly reduced by the immunosuppressive treatment
(Fig. 5E,F). Interestingly, the numbers of IL-17A-producing T
cells were also substantially inhibited (Fig. 5G). CsA+Rapa
treatment resulted in a substantial reduction of Foxp3+ cells in
both the human skin graft and spleen (data not shown).
Next, using flowcytometry, we analyzed the effect of CsA and
Rapa treatment on the systemic immune response. We found that
following CsA and Rapa treatment the number of human CD4+
and CD8+ T cells was reduced in peripheral blood of the mice
(CD4+, 6,66610566,086103 vs 1,47610562,786104 and CD8+,
5,78610565,516103 vs 1,96610561,006105 total cell numbers,
no treatment vs CsA+Rapa, resp. (p,0,01) Fig. 6A).
Moreover, after CsA and Rapa treatment the number of
proliferating (Ki67 expressing) (Fig. 6B) and activated/differen-
tiated (CD45RO expressing) (Fig. 6C) human CD4+ and CD8+
T cells in the peripheral blood was substantially decreased.
Discussion
In our current work we further advanced the huPBL-SCID-
huSkin allograft model initially described Pober’s group [5,6] for
studying local skin inflammation, by identifying new local (skin) –
as well as systemic parameters that turn this model into an even
more powerful tool to study human skin immunopathology in vivo.
A good understanding of the human skin immunopathology is
crucial in the development of novel therapeutics for the treatment
of (auto) inflammatory skin diseases.
Although the major focus of the huPBL-SCID-huSkin allograft
model is on skin immune pathology, we also directed our attention
on the systemic immune response of the human PBMC. We here
demonstrate systemic proliferation, activation, and induction of
homing marker acquisition by human T cells. This was prevented
by systemic treatment with the immunosuppressive agents CsA
Figure 3. Infiltration of human IL-17A-producing T cells and CD4+ Foxp3-expressing T cells in the inflamed human skin in the SCID/
skin allograft mouse model. A. Immunohistochemistry of human CD4 (brown, top) and CD8 (brown, bottom) expression in human skin grafts
from SCID beige mice 21 days after infusion or huPBMC. Photographs show representative examples. 206magnification. B. Summarized data of
figure A. showing mean6SEM CD4 (top) or CD8 (bottom) positive cells/mm2 of n= 4 and 10 upon PBS and huPBMC infusion resp in the epidermis
(white bars) and dermis (black bars). C. Immunohistochemistry of human IL-17A expression in human skin grafts from SCID beige mice 21 days after
infusion of PBS (left) or huPBMC (right). Photographs show representative examples of n = 6 (huPBMCs) n = 3 (controls). 206magnification. Graph
shows summarized data of IL-17A positive cells/mm2 following PBS or huPBMC infusion in the human skin biopsies (mean6SEM, of n = 4 and 10). D.
Immunohistochemistry of coexpression of human CD4 (blue) and IL-17A (red, top) and CD8 (blue) and IL-17A (red, bottom) in human skin grafts from
SCID beige mice 21 days after infusion of huPBMC (206magnification). Inserts show a higher magnification (406) of single CD4/CD8 and IL-17A
staining and CD4/IL-17A or CD8/IL-17A co-staining. . Photographs show representative examples of n = 6. E. Immunohistochemistry of IL-17A (red) in
human mastcell tryptase (brown) and granulocyte elastase (brown) in human skin biopsies from SCID beige mice 21 days after infusion of PBS (left) or
huPBMC (right). Photographs show representative examples of n = 6 (huPBMCs) n = 3 (controls). 206magnification. F. Immunohistochemistry of co-
expression of human Foxp3 (brown) and CD4 (blue) in human skin grafts from SCID beige mice 21 days after infusion of PBS (left) or huPBMC (right)
(406magnification). Inserts show a higher magnification (636) of single Foxp3 and CD4+ staining and Foxp3/CD4 co-staining. Photographs show
representative examples of n= 6 (huPBMCs) n = 3 (controls).
doi:10.1371/journal.pone.0045509.g003
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and Rapa. Systemic analysis of the immune response in this
preclinical humanized model is important for two reasons. First,
the induction of a local T cell immune response is a multistep
phenomenon taking place locally at the affected skin site (antigen
recognition), in the draining lymph nodes (antigen presentation, T
cell activation, differentiation, expansion) and peripheral blood
(migration of activated T cells to the affected site and to other
lymph nodes) [14]. Second, during the last decade there is an
increasing use of systemic agents, like anti-inflammatory drugs or
biologicals, to treat severe inflammatory skin diseases [23] [24]. At
present, little Information is available on the effects of systemic
medication of immune modulating agents and their effects on the
systemic immune response in humanized mouse models. This
information is crucial to identify treatment-related systemic
biomarkers for immunomonitoring of patients undergoing clinical
trials. For analysis of the systemic human immune response in the
huPBL-SCID-huSkin model, peripheral blood samples containing
relatively few cells can be used to analyze the effects of an anti-
inflammatory drug by multi-color flowcytometry over time.
In the huPBL-SCID-huSkin model we observed that the
presence of the human skin graft instructs CLA expression on a
fraction of the peripheral human CD8+ T cells. This suggests that
migration of T cells from skin or skin draining lymph nodes to the
periphery is taking place. In mice it has been demonstrated that
memory/effector phenotype T cells migrated from the skin to the
draining lymph nodes in the steady state conditions, and this
process was increased during a cutaneous immune response [25].
Early in a primary cutaneous immune response, proliferating T
cells were released from the skin-draining lymph nodes and
migrated via the circulation to antigen free lymph nodes that drain
other tissues [26]. This migration of dividing T cells from the skin
draining lymph nodes might explain the presence of human
dividing Ki67+ T cells that we identify in the peripheral blood and
spleen in the huPBL-SCID-huSkin model. Little is known about
the migratory capacity of human T cells in vivo, the huPBL-SCID-
huSkin model will be a helpful tool in improving our understand-
ing in this respect.
IL-17-producing CD4+ T cells, designated Th17 cells, are
important in the protection against extracellular pathogens, but
Th17 cells are also associated with inflammatory and autoimmune
conditions in humans [27]. IL-17 is a cytokine that acts as a potent
proinflammatory mediator by increasing chemokine production to
recruit monocytes and neutrophils to the site of inflammation.
Immunity mediated by Th17 cells is particularly important at
epithelial and mucosal surfaces [28]. IL-17-producing T cells
appear to be important in the pathogenesis of psoriasis; Th17 cells
have been demonstrated by both immunohistochemistry and
flowcytometry in psoriatic lesions [17,18]. Furthermore, a recent
phase-II clinical study with a human antibody to IL-17A (AIN457,
secukinumab) in psoriasis patients showed promising results
supporting a role for Th17 in the pathophysiology of psoriasis
[19]. Also in the early stages of atopic dermatitis IL-17-producing
cells seem to contribute to the pathology of the disease [20,21]. In
the inflamed skin of the huPBL-SCID-huSkin model we observed
the presence of IL-17A-producing CD4+ and CD8+ cells.
Although Th17 cells, which are classically defined as CD4+ IL-
17-producing cells, previously has received the major focus, it has
recently been established that also CD8+ IL-17-producing cells
contribute to inflammatory skin disorders including psoriasis
[29,30].
Regulatory T cells are important in the control of immune
homeostasis and tolerance [31]. In particular CD4+ regulatory T
cells expressing the Treg master transcription factor Foxp3 were
extensively studied over the last decade. Skin resident CD4+
Foxp3+ Treg were identified in mice and men [25,32]. In mice,
skin resident CD4+Foxp3+ Treg suppress inflammation and
appear to migrate from the skin to the draining lymph nodes
under steady state conditions. During a cutaneous immune
response migration of Treg was increased [25,32]. Moreover,
Treg that migrated from the skin returned to the skin upon skin
antigen exposure [25]. In normal human skin under steady state
conditions between 5 and 10% of the skin resident T cells are
CD3+/FOXP3+ Treg [33] and proliferation of CD4+/Foxp3+
Treg was induced after a cutaneous challenge [34]. Together these
data suggest that Treg circulate between blood, skin, and
lymphoid tissues and that local Treg proliferation takes place in
order to regulate peripheral skin immune responses. In the
affected human skin of the huPBL-SCID-huSkin model, we now
demonstrate the presence of human CD4+Foxp3+ T cells in the
dermis of the human skin, which suggests active immune
regulation in the inflamed human skin of this humanized mouse
model. A possible reason why Foxp3+ Treg in this model do no
inhibit the IL-17A production by CD4+ and CD8+ T cells might
be explained by the fact that Treg can become unstable under
proinflammatory conditions and lose suppressor function and even
gain pro-inflammatory characteristics, resulting in an increased
inflammatory response [35]. Also human Treg have this propen-
sity to convert into proinflammatory cytokine secreting cells, in
particular when activated under proinflammatory conditions [36].
We studied gene expression levels of cytokines and chemokines
by quantitative real-time PCR in the affected human skin of the
mice 3 weeks after the inoculation with PBMC when inflammation
of the human skin was established. We found an increase in gene
expression of human IL1B, IL6, IL8, CXCL1, CXCL10, CCL5
Figure 4. Systemic human CD4 and CD8 T cell activation, proliferation and acquisition of homing markers in the SCID/skin allograft
mouse model. A. Flowcytometry showing side scatter (SSC, X-axis) and CD45 expression (Y-axis) (top panel) and CD4 (X-axis) and CD8 (Y-axis)
expression (lower panel) in peripheral blood and lymph node and spleen cell suspensions 21 days after infusion or huPBMC. Representative dotplots
are shown (n= 4–7). CD4/CD8 expression is shown after gating on huCD45+ cells. In case of PBS infusion hardly any human CD45+ lymphocytes was
detected (data not shown). B. Summarized flowcytometry data of human CD4+ and CD8+ cells upon huPBMC infusion as shown in A. (n = 6). C.
Flowcytometry of human CD45RO+ (X-axis) and CD45RA+ (Y-axis) cell populations in peripheral blood and lymph node and spleen cell suspensions
21 days after infusion of huPBMC in SCID beige mice that either lacked (top panel) or were previously grafted with human skin (lower panel)
Representative dotplots gated on huCD45+ cells are shown. D. Summarized flowcytometry data of CD45RO+ and CD45RA+ cells upon huPBMC
infusion in SCID beige mice that were grafted with human skin as shown in C. (n = 6). E. Flowcytometry of Ki67 expression in CD4+ (top panel) and
CD8+ (lower panel) human T cells in peripheral blood (left) and spleen (right). F. Summarized flowcytometry data of Ki67 expression in CD4+ and
CD8+ human T cells as shown in E. (n = 6). G. Flowcytometry of CLA (top panel) and CD62L (lower panel) expression on human CD3+ cells
populations in peripheral blood, 21 days after infusion of huPBMC in SCID beige mice that either lacked (right panel) or were previously grafted with
human skin (right panel) Representative dotplots gated on huCD45+ cells are shown. H. Summarized flowcytometry data of CLA and CD62L
expression on human CD3+ cells as shown in G. (n = 4–5). I. Flowcytometry of CLA (top panel) and CD62L (lower panel) expression on human CD4+
(left) and CD8+ (right) cells in peripheral blood, 21 days after infusion of huPBMC in SCID beige mice that previously grafted with human skin.
Representative dotplots gated on huCD45+ cells are shown. J. Summarized flowcytometry data of CLA and CD62L expression on human CD4+ and
CD8+ cells as shown in peripheral blood, lymph nodes and spleen. (n = 4–5).
doi:10.1371/journal.pone.0045509.g004
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and DEFB4. The upregulation of DEFB4 correlated with the
increased protein levels of hBD2 found by immunohistochemistry.
Besides the chemokines and cytokines presented in figure 2C, we
analyzed a number of other relevant cytokines that might play a
role in skin inflammation (such as IL12, IL23, IL17, and IL22).
Gene expression levels of these cytokines, arising from immune
cells, were close to or below the detection limit. The reason for this
is probably related to the fact that we have been analyzing gene
expression at a late time point when overt inflammation was taken
place (3 weeks after infusion of human PBMC) combined with the
low levels of immune cells compared to keratinocytes in the skin
biopsy. Future studies are needed to reveal time-kinetics of gene
expression.
In the humanized inflammatory skin model that we here
present, we showed differential expression of epidermal pathology-
related proteins such as increased human b-defensin-2, Elafin,
Keratin 16 (K16), and Ki67 levels, and reduced expression of
Keratin 10 (K10). Most chronic inflammatory skin diseases are
characterized by increased proliferation of keratinocytes, resulting
in epidermal thickening (acanthosis). Proliferating keratinocytes
are further characterized by upregulation of the proliferation
marker Ki67. The proliferative response is further accompanied
by a shift in keratin expression in the supra-epidermal layers. K16
is upregulated, while K10 is downregulated in keratinocytes. K16
expression, which is not expressed in healthy epidermis, was first
explained as the specific result of hyperproliferation. However,
more recent studies show K16 expression to be a marker of
general trauma and stress of the skin ([37,38]. Elafin and hBD-2
are anti-microbial peptide/proteins secreted by keratinocytes, they
constitute part of the innate immune defense and participate in
skin protection against invading microorganisms [39]. Elafin and
hBD-2 are not present in healthy human epidermis, but they are
highly induced under chronic inflammatory conditions of the skin
(eg. psoriasis) and in case of skin barrier disruption [40–43]. The
proinflammatory cytokine IL-17A can induces the expression of
hBD2 in keratinocytes [44–46]. Next to its antimicrobial activity,
hBD2 acts as pro-inflammatory chemoattractant for immune cells
such as T-cells, dendritic cells, mast cells and neutrophils [47]. The
upregulation of these anti-microbial peptides in our model is most
likely the result of the influx of activated T cells and other immune
cells and points to involvement of the innate immune system and
impaired skin barrier function.
Psoriasis is a highly prevalent T cell mediated chronic
inflammatory skin disease, which has both environmental and
genetic causes to its etiology [48,49]. The multi factorial and
complex pathophysiology of the disease results in disturbed
communication between cells of the immune system and
epidermal cells, leading to abnormal differentiation and hyper-
proliferation of keratinocytes [50]. Recently it emerged that the
disease is strongly associated with IL-23 [51] and IL-17-producing
T helper cells [17–19]. Psoriatic plaque lesions are histologically
characterized by an increase in epidermal thickness, caused by
disturbed keratinocyte differentiation and hyper proliferation
(acanthosis), elongated epidermal rete ridges and influx of immune
Figure 5. Cyclosporin-A and rapamycin treatment restores aberrant human epidermal differentiation marker expression and
prevents infiltration of inflammation associated IL-17A producing human T cells of the human skin in the huPBL-SCID/skin
allograft mouse model. A. Macroscopic (top panel) and histological (H&E) (lower panel) appearance of human skin graft from SCID beige mice 21
days after infusion of huPBMC with no treatment (left panel) and treatment with CsA and Rapa (right panel). B. Quantitative microscopic histological
analysis of the epidermal thickness (mm) of skin grafts following infusion of huPBMC with or without CsA and Rapa. Mean6SEM are shown for n = 3
and 5 upon PBS and huPBMC infusion resp. 206magnification. C. Immunohistochemistry of K10, K16, hBD2 and Elafin in human skin grafts from
SCID beige mice 21 days after infusion (i.p.) of huPBMC without (top panel) and with CsA and Rapa treatment (lower panel). Representative examples
are show. 106magnification. D. Summarized data represented in C are given in the figures. Mean6SEM percentages of the area positive for the
indicated markers is shown for n = 3 and 4–6 upon no treatment and treatment with CsA and Rapa, resp. E. Immunohistochemistry of CD4 (top
panel) and CD8 (lower panel) in human skin grafts from SCID beige mice 21 days after infusion (i.p.) of huPBMC without (left panel) and with CsA and
Rapa treatment (right panel). Representative examples are show. 206magnification. F. Summarized data represented in E. are given in the figures.
Mean6SEM percentages of CD4 (top) and CD8 (bottom) positive cells is shown for n = 3 and 4–5 upon no treatment and treatment with CsA and
Rapa, resp. G. Immunohistochemistry of IL-17A (brown) (representative examples of n = 5 are shown) 106magnification. Graph shows summarized
data of IL-17A positive cells/mm2 present in human skin biopsies following infusion of huPBMC in the absence or presence of Rap/CsA resp.
(mean6SEM, of n = 3 and 4–5).
doi:10.1371/journal.pone.0045509.g005
Figure 6. Cyclosporin-A and rapamycin treatment prevents systemic activation and proliferation of human CD4+ and CD8+ T cells
in the huPBL-SCID/skin allograft mouse model. A. Enumeration of CD4+ and CD8+ cell populations by flowcytometry in peripheral blood 21
days after infusion of huPBMC without (white bars) or with CsA (black bars) and Rapa. Summarized flowcytometry data are presented (n = 6). B.
Flowcytometry of Ki67 in human CD4+ of CD8+ cells in peripheral blood 21 days after infusion of huPBMC without (white bars) or with CsA and Rapa
(black bars). Summarized data of n = 6 are shown. C. Flowcytometry of CD45RO and CD45RA expression on human CD3+ T cells in peripheral blood
after infusion of huPBMC without (white bars) or with CsA and Rapa (black bars). Summarized data of n = 6 are shown.
doi:10.1371/journal.pone.0045509.g006
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cells among which many T cells [50]. Clinically these alterations
are represented by scaling, plaque thickening, and erythema [50].
At the molecular level, a regenerative epidermal differentiation
program is induced that includes expression of genes such as
Keratin 16 (K16), elafin, psoriasin and b-defensin-2 (hBD-2), and
because differentiation is impaired keratinocytes loose expression
of normal supra-basal keratin-10 (K10) [52–55] and increase
expression of Ki67 in basal keratinocytes [50]. The association of
psoriasis and hBD-2 induction [52] has recently been further
substantiated by demonstrating increased b-defensin copy num-
bers in psoriasis patients [42].
In the inflamed human skin of the huPBL-SCID-huSkin model
we here demonstrate that the skin inflammatory phenotype
resembles human plaque-type psoriasis at multiple levels; macro-
scopically we found erythema and skin thickening, microscopically
using histology we demonstrated acanthosis, parakeratosis and
psoriasis like rete ridges, and by immunohistochemistry we found
increased expression of hBD-2, elafin, K16 and Ki67 and reduced
K10 expression. Moreover, we detected CLA expressing human
CD8+ T cells in the peripheral blood of the huPBL-SCID-huSkin
model. The presence of CLA-expressing CD8+ T cells in the
peripheral blood of psoriasis patients is a hallmark of the disease
[56,57]. Most of the huPBMC-induced changes were significantly
inhibited or completely prevented after CsA and Rapamycin
treatment. Together these findings suggest that the huPBL-SCID-
huSkin model is of potential interest to study the pathology of
psoriasis at the level of skin and immune biology.
In conclusion, employing the huPBL-SCID-huSkin allograft
model of human skin inflammation combined with the local and
systemic markers for human cells that we here identified enable
preclinical evaluation of novel immuno-modulating agents and
cell-based therapy. Also, it will contribute to our understanding of
inflammatory and regulatory processes by human T cells and
keratinocytes in the pathology of skin inflammatory disorders in
vivo.
Materials and Methods
Mice
Female B17.B6-PrkdcscidLyst bg/Crl (SCID/beige) mice, 6–8
weeks old, were purchased from Charles River Breeding
Laboratories and housed in the SPF facility of the Central Animal
Laboratory of the RUNMC. All the animal experimental
procedures were in accordance with the international welfare
guidelines taking in consideration the 3Rs (Refinement, Reduc-
tion, Replacement) and approved by the institutional ethical
animal care committee of the Radboud University Nijmegen
(number 2008167).
Humanized mouse model; huPBL-SCID-hu Skin allograft
model
The huPBL-SCID-hu Skin allograft model used in our study is
with slight adaptations based on the model described by Murray et
al. [5]. Superficial human skin, 600 to 700 mm thick, was
harvested using a dermatome and kept in culture medium with
penicillin/streptavidin at 4uC and within max. 30 hours trans-
planted onto the back of SCID/beige mice. Abdominal skin from
healthy individuals was obtained from elective surgeries through
the RUNMC Department of Plastic Surgery. After healing of the
human skin (21 days), 1506106 ficoll density gradient isolated
(Lymphoprep; Nycomed-Pharma AS, Oslo, Norway) human
peripheral blood mononuclear cells (huPBMC), obtained from
buffy coats of blood donors, purchased from Sanquin Blood Bank,
Nijmegen, The Netherlands, were infused intra peritoneally (i.p) in
a volume of 0.8 ml PBS. Mice were killed at the end of the
experiment and tissues of interest were collected.
The use of human skin and peripheral blood were approved and
in accordance with the regulations set by the Medical Ethical
Committees for human research of the RUNMC. Human skin
and buffy coats from healthy donors, who gave written informed
consent for scientific use of the human materials. Buffy coats were
purchased from Sanquin Blood Bank, Nijmegen, The Netherlands
Drug treatment
Cyclosporine–A (Sandimmune, NovartisH) was administered at
a concentration of 0.4 mg/kg/day s.c. via mini-osmotic pump
(pumping rate was 1 ml/h , reservoir volume 200 ml). The control
group was implanted with a mini-osmotic pump filled with PBS.
Rapamycin was injected intraperitoneally (i.p.) at a dose of
0.4 mg/kg body weight in a volume of 100 mL PBS at alternating
days, starting 7 days after the infusion of huPBMC.
Histology & Immunohistochemistry
Human skin grafts were fixed in neutral buffered 4% formalin
(Mallinckrodt Baker, Inc Deventer, The Netherlands) for 4 hours,
processed and embedded in paraffin. Sections (6 mm) were stained
with hematoxilin-eosin (HE) or processed for immunohistochem-
ical staining.
Keratinocyte differentiation was analyzed using primary,
antibodies directed against: Elafin (rabbit 92-1), hBD-2 (ab9871,
Peprotech, London,UK), K10 (RKSE60, Eurodiagnostica) and
K16 (LL025, Novocastra Laboratories, Newcastle upon Ty-
ne,UK). Cell division was studied using antibodies against Ki67
(MiB-1, Dako cytomation). To enumerate CD4+ and CD8+ T
cells antibodies against CD4 (BC/F6, Santa Cruz Biotechnology,
Santa Cruz, CA) and CD8 (144B, Dako Cytomation) were used.
IL-17 production was detected using polyclonal goat IL-17A
antibody (R&D-systems). To detect Foxp3 expression anti-FoxP3
(PCH101) was used. To detect the presence of human neutrophils
and mast cells, antibodies against human neutrophil elastase
(NP57; Dako) or human mast cell tryptase (AA1; Dako) were used.
Antibody stainings were visualized using the Dako Cytomation
EnVision+system-HRP (ABC) kit (DAKO, Glostrup, Copenha-
gen, Denmark) combined with 3,39-diaminobenzidine tetrahy-
drochloride (DAB, brown) (Sigma-Aldrich, St. Louis, USA) or
using that Labeled Streptavidin Biotin method (Universal LSAB
Kit/AP; Dako) combined with either Permanent Red (Dako) or 5-
Bromo-4-Chloro-3-Indolyl Phosphate/Nitro Blue Tetrazolium
(BCIP/NBT) (Dako).
Sections were photographed using a microscope (Axiokop2
MOT; Zeiss, Sliedrecht, the Netherlands), digital camera
(Axiocam MRc5; Zeiss) and AxioVision software (Zeiss).
Image analysis of immunohistochemistry
To enumerate huCD4+ and huCD8+ cells, representative
pictures were made at 106magnification. A representative region
of interest (ROI) was drawn from the lowest epidermal papilla till
300 mm dept into the dermis. Cell quantification was performed
by setting a threshold and relating this to a number of cells per
mm2. For evaluation of number of CD4+ and CD8+ IL-17A-
secreting cells, double positively stained cells were counted
manually in CD4 CD8 infiltrated areas of the tissues and the
numbers were reported per mm2. Ki67+ cells were counted
manually and related to the length of basement membrane (BM).
For quantification of hBD-2, Elafin, K10 and K16 positive cells,
photographs were made at 106 magnification. The total
epidermal area and K10 or K16 positive area was measured in
the ROI (epidermal compartment). Epidermal differentiation was
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defined as: % K10 or K16 positive epidermal area. Each photo
was analyzed using ImageJ software (NIH, http://rsb.info.nih.
gov/ij).
Determination of epidermal thickness
Histologic assessment of the grafts was performed by light
microscopy both before and after transplantation of human skin.
The mean epidermal thickness was calculated using the program
Visiopharm Integrator System (VIS) (Visiopharm, Hørsholm,
Denmark) as epidermal area divided by epidermal surface length.
Flowcytometry
Mesenteric/peripheral lymph nodes and spleen were processed
to obtain a single cell suspension. Retro-orbital blood samples
were collected and lymphocytes were isolated by density gradient
centrifugation. For cell surface staining, the following conjugated
mAbs were used: anti-CD45 PE (Beckman-Coulter), anti-CD3 PE
(Beckman-Coulter), anti-CD4 PE-Cy7 (SFCI12T4D11, Beckman-
Coulter), anti-CD8 PE-Cy5(B9.11 , Beckman-Coulter), anti-
CD62L (DREG56, Beckman-Coulter) anti-CD45RA FITC
(HI100, BD), anti-CD45RO ECD (UCHL1, Beckman-Coulter)
and anti-CLA FITC (HECA-452, BD). Intracellular Foxp3
staining was performed after fixation and permeabilization of
the cells as indicated by the supplier (Ebioscience). Cell samples
were measured on a 5 color FC500 flowcytometer (Beckman-
Coulter), and the data were analyzed using CXP software
(Beckman-Coulter).
Gene expression analysis
Tissues were homogenized using a TissueLyser (Qiagen). RNA
was extracted using the RNeasy Lipid Tissue Mini Kit (Qiagen)
and reverse-transcribed by use of the High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems). The samples were
amplified by quantitative real-time PCR using Applied Biosystems
validated gene expression assays and PRISM7900HT sequence
detection system (SDS 2.3). Expression of GAPDH was used for
normalization and fold changes calculated by the comparative Ct
method.
Gene expression assay ID: IL1B-Hs00174097_m1, IL6-
Hs00985639_m1, IL8-Hs00174103_m1, CCL5-
Hs00174575_m1, CCL20-Hs00171125_m1, CXCL1-
Hs00236937_m1, CXCL10-Hs00171042_m1, DEFB4-
Hs00823638_m1, IFNG-Hs00174143_m1, IL12B-
Hs00233688_m1, IL23A-Hs00372324_m1, IL17A-
Hs00174383_m1, IL22-Hs00220924_m1, IL20-
Hs00218888_m1, GAPDH-Hs99999905_m1.
Statistics
The results were analyzed by a two-tailed Mann Whitney t test
using GraphPad Prism software. *, P value,0.05; **, P
value,0.01; ***, P value,0.001.
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